• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Exploration of novel anticancer activity via bioactive lipid mediators including resolvins E2/E3

Research Project

Project/Area Number 21K09459
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56040:Obstetrics and gynecology-related
Research InstitutionHyogo Medical University

Principal Investigator

Tsubamoto Hiroshi  兵庫医科大学, 医学部, 教授 (80340975)

Co-Investigator(Kenkyū-buntansha) 上田 友子  兵庫医科大学, 医学部, 助教 (50793585)
井上 佳代  兵庫医科大学, 医学部, 非常勤講師 (80594754)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords腫瘍微小環境 / 腫瘍関連マクロファージ / 再分極 / レゾルビン / イトラコナゾール / 脂質メディエーター / ドラッグ・リポジショニング
Outline of Research at the Start

本研究では、イトラコナゾールの新規抗がん作用機序を同定する。子宮頸癌の26%がPIK3CA変異を有しておりCaSki細胞もPIK3CA p.E545K変異を有し、これまでの我々の検討では多癌腫も含めて最もイトラナゾールによる増殖抑制効果を認めている。従ってこの細胞を用いる。我々のこれまでの研究により生物活性脂質メディエーターであるレゾルビンE2・レゾルビンE3の関与が示唆されているが、抗がん作用機序としては未知の代謝経路であり新規作用機序の解明として期待できる。イトラコナゾールのレゾルビンE2/E3を介する腫瘍への直接作用及びマクロファージを介した間接的抗腫瘍効果を明らかにする。

Outline of Final Research Achievements

A novel mechanism of action of itraconazole is the production of eicosapentaenoic acid-derived resolvins E2/E3. Inhibition of these metabolic pathways with ML351, a 12/15-LOX inhibitor, interfered with the action of itraconazole on CaSki cells. Suggesting an association with resolvin E2/E3-mediated TAM, M2 TAM was converted to M1 by itraconazole, and CaSki cell growth was suppressed in culture supernatants and co-cultures of M2 TAM after ITZ treatment. Single-cell analysis and three-color fluorescent immunostaining suggested that the mechanism of action was impaired lysosomal cholesterol transport.

Academic Significance and Societal Importance of the Research Achievements

イトラコナゾールの作用機序がわかった。現在、ITZのターゲットの同定を試みている。TAM再分極を標的とした薬剤は臨床応用されておらず、同定されれば多癌種のTAMに対する新規治療薬開発が期待できる。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (3 results)

All 2023 2021

All Journal Article (3 results) (of which Peer Reviewed: 3 results)

  • [Journal Article] . Itraconazole Repolarizes Tumor-associated Macrophages and Suppresses Cervical Cancer Cell Growth.2023

    • Author(s)
      Takimoto Y, Tsubamoto H, Taniguchi R, Sakata K, Takada Y, Adachi J, Tomonaga T, Ueda T, Nakagawa K, Narita S, Wakimoto YU, Shibahara H.
    • Journal Title

      Anticancer Res.

      Volume: 43 Issue: 2 Pages: 569-580

    • DOI

      10.21873/anticanres.16193

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Itraconazole Modulates Phospholipid Levels in Tumor-associated Macrophages2023

    • Author(s)
      Takimoto Y, Tsubamoto H, Isono-Taniguchi R, Ueda T, Sakata K, Nakagawa K, Narita S, Wakimoto YU, Shibahara H, Nishiumi S.
    • Journal Title

      Anticancer Res.

      Volume: 43 Issue: 5 Pages: 1981-1984

    • DOI

      10.21873/anticanres.16358

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Itraconazole Increases Resolvin E3 Concentration and 12/15-lipoxygenase Inhibitor Attenuates Itraconazole Cytotoxicity in Cervical Cancer Cells2021

    • Author(s)
      Isono R, Tsubamoto H, Inoue K, Ueda T, Takimoto Y, Sakata K, Shinohara M, Shibahara H.
    • Journal Title

      Anticancer Res

      Volume: 41 Issue: 9 Pages: 4271-4276

    • DOI

      10.21873/anticanres.15231

    • Related Report
      2021 Research-status Report
    • Peer Reviewed

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi